MXPA00006306A - Compuestos del canal de ion del cerebro o corazon, regulados por nucleotidos ciclicos y usos de los mismos. - Google Patents

Compuestos del canal de ion del cerebro o corazon, regulados por nucleotidos ciclicos y usos de los mismos.

Info

Publication number
MXPA00006306A
MXPA00006306A MXPA00006306A MXPA00006306A MXPA00006306A MX PA00006306 A MXPA00006306 A MX PA00006306A MX PA00006306 A MXPA00006306 A MX PA00006306A MX PA00006306 A MXPA00006306 A MX PA00006306A MX PA00006306 A MXPA00006306 A MX PA00006306A
Authority
MX
Mexico
Prior art keywords
bcng
present
protein
provides
related protein
Prior art date
Application number
MXPA00006306A
Other languages
English (en)
Inventor
Gareth Tibbs
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/997,685 external-priority patent/US6551821B1/en
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of MXPA00006306A publication Critical patent/MXPA00006306A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

La presente invencion proporciona un acido nucleico aislado que codifica una proteina BCNG o una parte de la misma o, una proteina relacionada con BCNG o una parte de la misma. La presente invencion proporciona adicionalmente un metodo para identificar un acido nucleico en una muestra la cual codifica un proteina BCNG o una proteina relacionada con BCNG. La presente invencion tambienproporciona unmetodo para probar siun compuesto afecta la expresion de una proteina BCNG o una proteina relacionada ocn BCNG. Ademas, la presente invencion proporciona adicionalmente un metodo para identificar un compuesto que tiene la capacidad de interactuar con una proteina BCNG o con una proteina relacionada con BCNG. Tambien la presente invencion proorciona un metodo para identificar un compuesto que tiene la capacidad para modular la actividad de la proteina BCNG o de la proteina relacionada con BCNG. Adicionalmente, la presente invenci6n proporciona un metodo para tratar una condicion en un sujeto, comprendiendo dicho metodo la administracion a dicho sujeto de una cantidad del compuesto proporcionado, efectiva para tratar la condicion. Finalmente, la presente invencion proporciona una composicion farmaceutica la cual comprende el compuesto proporcionado y un transportador farmaceuticamente aceptable.
MXPA00006306A 1997-12-23 1998-12-23 Compuestos del canal de ion del cerebro o corazon, regulados por nucleotidos ciclicos y usos de los mismos. MXPA00006306A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/997,685 US6551821B1 (en) 1997-12-23 1997-12-23 Brain cyclic nucleotide gated ion channel and uses thereof
US09/086,436 US6703485B2 (en) 1997-12-23 1998-05-28 Brain and heart cyclic nucleotide gated ion channel compounds and uses thereof
PCT/US1998/027630 WO1999032615A1 (en) 1997-12-23 1998-12-23 Brain or heart cyclic nucleotide gated ion channel compounds and uses thereof

Publications (1)

Publication Number Publication Date
MXPA00006306A true MXPA00006306A (es) 2004-09-10

Family

ID=26774756

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA00006306A MXPA00006306A (es) 1997-12-23 1998-12-23 Compuestos del canal de ion del cerebro o corazon, regulados por nucleotidos ciclicos y usos de los mismos.

Country Status (9)

Country Link
US (2) US6703485B2 (es)
EP (2) EP1042460B1 (es)
JP (1) JP2002508930A (es)
AT (1) ATE296880T1 (es)
AU (1) AU2016099A (es)
CA (1) CA2315891A1 (es)
DE (1) DE69830422T2 (es)
MX (1) MXPA00006306A (es)
WO (1) WO1999032615A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19806581A1 (de) * 1998-02-17 1999-10-21 Forschungszentrum Juelich Gmbh Sequenzen eines Ih-Ionenkanals und deren Verwendung
DE10006309A1 (de) 2000-02-12 2001-08-23 Aventis Pharma Gmbh Verfahren zur Identifizierung von Substanzen, die die Aktivität von hyperpolarisationsaktivierten Kationen-kanälen modulieren
AU2001272421A1 (en) * 2000-05-24 2001-12-03 Akzo Nobel N.V. Full length human hcn1 ih channel subunit and variants
US20040033943A1 (en) * 2000-07-03 2004-02-19 Strijbos Paul Johannes Leonardus Maria Hcn polypeptides and polynucleotides and their use in therapy
AU2001271839A1 (en) * 2000-07-05 2002-01-14 Pharmacia And Upjohn Company Human ion channels
CA2421584C (en) * 2000-09-06 2013-12-31 Johns Hopkins University Gene therapy for cardiac arrythmias
US20090175790A1 (en) * 2000-09-06 2009-07-09 The Johns Hopkins University Cardiac arrhythmia treatment methods and biological pacemaker
US20050014141A1 (en) * 2001-01-23 2005-01-20 Folander Kimberly L. Human hyperpolarization-activated cyclic nucleotide-gated cation channel hcn1
EP1409510A4 (en) * 2001-04-27 2004-09-08 Univ Johns Hopkins BIOLOGICAL HEART PACEMAKER
JP2006508073A (ja) * 2002-10-02 2006-03-09 ザ・ジョンズ・ホプキンス・ユニバーシティー 限局的カルシウムチャネル調節方法
WO2005062954A2 (en) * 2003-12-23 2005-07-14 The Trustees Of Columbia University In The City Of New York Modulation of hcn channels by second messengers
US8859273B2 (en) * 2003-12-24 2014-10-14 Medtronic, Inc. Methods of using HCN genes to treat cardiac arrhythmias
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
CA2626067A1 (en) * 2005-10-14 2007-04-26 The Johns Hopkins University Biologically excitable cells
AU2007343796A1 (en) * 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
MX2009012609A (es) * 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
JP5759664B2 (ja) * 2008-08-29 2015-08-05 花王株式会社 Ｃｎｇチャネル阻害剤
US20110301568A1 (en) * 2010-06-04 2011-12-08 Medtronic, Inc. Systems and Methods to Treat Cardiac Pacing Conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US118988A (en) * 1871-09-12 Improvement in hot-air furnaces
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US6551821B1 (en) * 1997-12-23 2003-04-22 The Trustees Of Columbia University In The City Of New York Brain cyclic nucleotide gated ion channel and uses thereof

Also Published As

Publication number Publication date
EP1042460A4 (en) 2001-12-19
ATE296880T1 (de) 2005-06-15
US20030118988A1 (en) 2003-06-26
US6703485B2 (en) 2004-03-09
AU2016099A (en) 1999-07-12
JP2002508930A (ja) 2002-03-26
CA2315891A1 (en) 1999-07-01
EP1609856A2 (en) 2005-12-28
WO1999032615A1 (en) 1999-07-01
US20040142421A1 (en) 2004-07-22
EP1042460A1 (en) 2000-10-11
DE69830422D1 (de) 2005-07-07
EP1042460B1 (en) 2005-06-01
DE69830422T2 (de) 2006-02-02
EP1609856A3 (en) 2006-04-05

Similar Documents

Publication Publication Date Title
MXPA00006306A (es) Compuestos del canal de ion del cerebro o corazon, regulados por nucleotidos ciclicos y usos de los mismos.
AU3368497A (en) Human dnase i hyperactive variants
AU3847997A (en) Inhibitors of the interaction between P53 and MDM2
EP0692972A4 (en) PROCESS FOR PROVIDING PROFILEABLE COMPOSITIONS TO PILED FOLLICLES
AU5624699A (en) Use of 5ht-6 antagonists
YU38801A (sh) Azabicikloalkani kao modulatori ccr5
HK1071890A1 (en) Spiroazacyclic compounds as monoamine receptor modulators
MX9604985A (es) Cardiotropina y usos de la misma.
MX9602517A (es) Naftiloamidas como agentes del sistema nervioso central.
WO1998014596A3 (en) Disease associated protein tyrosine phosphatases
YU66000A (sh) Antipikovirusna jedinjenja, njihovo dobijanje i upotreba
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
AU6745287A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
WO1998011234A3 (en) Human protein kinases
Dahel et al. Polyamine oxidase activity in sera of depressed and schizophrenic patients after ECT treatment
DE69924877D1 (en) Humanes akt-3 protein
AP2000001937A0 (en) Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway.
MXPA02009781A (es) Isoformas de esfingosina cinasa tipo 2 de mamifero, clonacion, expresion y metodos de uso de las mismas.
WO1997014966B1 (en) Method of activating a novel ligand regulatory pathway
AU5327198A (en) Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy
DE60027928D1 (de) MENSCHLICHES, GEBäRMUTTERKREBS-SPEZIFISCHES SUPPRESSORPROTEIN, FüR DAS PROTEIN KODIERES POLYNUKLEOTID, MIT DEM POLYNUKLEOTID TRANSFORMIERTE ZELLE UND VERFAHREN ZUR UNTERDRüCKUNG DER PROLIFERATION VON KREBSZELLEN UNTER VERWENDUNG DES EXPRESSIONSVEKTORS
AU2347501A (en) Trp-protein-related mtr1 protein and dna sequence coding therefor
Ota et al. Nicotine-induced regulation of tyrosine hydroxylase activity in adrenal gland of transgenic mouse carrying human tyrosine hydroxylase gene
AU2001244151A1 (en) Peptide and nucleic acid coding therefor for the detection, diagnosis and therapy of diseases of the nervous system
WO2002088345A3 (en) Murine dnasex, medicament containing the same and non-human mammal comprising modified dnasex gene

Legal Events

Date Code Title Description
FA Abandonment or withdrawal